Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | The timing and choice of DMTs for MS patients

Jaume Sastre-Garriga, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, addresses several ongoing controversies in the field of multiple sclerosis (MS), including when certain patients should start therapy and which strategy should be used when starting treatment. Virtually all studies have shown that starting treatment as early as possible provides the best outcomes for patients. When comparing escalation strategy versus the use of high-efficacy (HE) disease-modifying therapies (DMTs) at early stages, evidence suggests that moving HE DMTs to earlier lines is the preferable approach. However, the escalation strategy may be a better option for certain patients and should still be considered. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J Sastre-Garriga has received grants and personal fees from Genzyme, personal fees from Almirall, Biogen, Celgene, Merck, Bayer, Biopass, Bial, Novartis, Roche and Teva, and he is European co-Editor of Multiple Sclerosis Journal and Scientific Director of Revista de Neurologia.